Fewer than one in 10 people that would benefit from GLP-1 drugs like Wegovy have access to them, states the World Health Organization as it releases its initial recommendations on the drugs.
With over a billion people worldwide currently classified as obese, it is urging increased and just availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with comprehensive and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant barriers to widespread availability to the jabs that can help people shift substantial body mass, says the organization.
Weight-Loss Drug Scarcity
Despite the present best projected case, the manufacturing of these medications might only reach about 100 million people – less than 10% of those who need them, as stated by the WHO.
The advice calls on governments and firms to widen availability, through measures including patent sharing.
Exclusive production rights on the active ingredient – the primary component of a leading brand – is due to expire in several countries in 2026.
How Obesity Jabs Function
These medications imitate a biological compound to slow digestion, reduce hunger and boost satiety so users eat less.
Individuals commonly see weight reduction within a few weeks of commencing the weekly injections.
Studies suggests patients may see weight return within a year of stopping the drug, as their usual hunger resume.
To be overweight or obese increases your likelihood for contracting diseases, including diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity impacts people in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
